Azithromycin is a 15-membered macrolide antibiotic that has antibacterial effects on a variety of Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms; its mechanism of action is the same as that of erythromycin, mainly binding to the 50S subunit of the bacterial ribosome, inhibiting RNA-dependent protein synthesis.

This product is a chloramphenicol antibiotic. It has a broad-spectrum antimicrobial effect in vitro, including aerobic Gram-negative and Gram-positive bacteria, anaerobes, Rickettsia, spirochetes and Chlamydia. It has bactericidal effects on the following bacteria: Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis. It only has antibacterial effects on the following bacteria: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Group B hemolytic Streptococcus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhi, Salmonella paratyphi, Shigella, Bacteroides fragilis and other anaerobic bacteria. The following bacteria are usually resistant to chloramphenicol: Pseudomonas aeruginosa, Acinetobacter, Enterobacter, Serratia marcescens, indole-positive Proteus, methicillin-resistant Staphylococcus and Enterococcus. This product is an antibacterial agent. Chloramphenicol is fat-soluble and enters bacterial cells by diffusion, and reversibly binds to the 50S subunit of the bacterial ribosome, which blocks the growth of the peptide chain (possibly due to the inhibition of the action of transpeptidase), thereby inhibiting the formation of the peptide chain and preventing protein synthesis.

By inhibiting bacterial transpeptidase, it prevents the synthesis of bacterial cell walls and inhibits or kills bacteria; when used in combination with trimethoprim, it can enhance antibacterial ability, delay the development of drug resistance, and reduce oral dosage.

By combining it with cephalexin, the antibacterial ability can be improved, the development of drug resistance can be delayed, and the oral dosage can be reduced.

By inhibiting bacterial transpeptidase, it prevents the synthesis of bacterial cell walls and inhibits or kills bacteria; when used in combination with trimethoprim, it can enhance antibacterial ability, delay the development of drug resistance, and reduce oral dosage.

By inhibiting bacterial transpeptidase, it prevents the synthesis of bacterial cell walls and inhibits or kills bacteria; when used in combination with cephalexin, it can enhance antibacterial ability, delay the development of drug resistance, and reduce oral dosage.